UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: A cluster analysis

Journal of the American Academy of Dermatology, 2023-05, Vol.88 (5), p.1101-1109

2023

Volltextzugriff (PDF)

Serum Interleukin-13 and Caspase 8 are Elevated in Prurigo Nodularis

Acta dermato-venereologica, 2023-02, Vol.103, p.adv00861-adv00861

2023

Volltextzugriff (PDF)

Interleukin‐33 antibody failed to demonstrate benefit in a phase II, double‐blind, randomized, placebo‐controlled study in adult patients with moderate‐to‐severe atopic dermatitis

British journal of dermatology (1951), 2022-10, Vol.187 (4), p.599-602

2022

Volltextzugriff (PDF)

Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: A cluster analysis

Frontiers in medicine, 2022-12, Vol.9, p.1011142-1011142

2022

Volltextzugriff (PDF)

IL-33 released by alum is responsible for early cytokine production and has adjuvant properties

Scientific reports, 2015-08, Vol.5 (1), p.13146-13146, Article 13146

2015

Volltextzugriff (PDF)

Human mast cells release the migraine-inducing factor pituitary adenylate cyclase-activating polypeptide (PACAP)

Cephalalgia, 2018-08, Vol.38 (9), p.1564-1574

2018

Volltextzugriff (PDF)

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab

Dermatology and therapy, 2023-07, Vol.13 (7), p.1535-1547

2023

Volltextzugriff (PDF)

Interleukin-33 Contributes Toward Loss of Tolerance by Promoting B-Cell-Activating Factor of the Tumor-Necrosis-Factor Family (BAFF)-Dependent Autoantibody Production

Frontiers in immunology, 2018-12, Vol.9, p.2871-2871

2018

Volltextzugriff (PDF)

Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33

Journal of inflammation research, 2021-01, Vol.14, p.3823-3835

2021

Volltextzugriff (PDF)

Elevated levels of Interleukin (IL)-33 induce bone pathology but absence of IL-33 does not negatively impact normal bone homeostasis

Cytokine (Philadelphia, Pa.), 2016-03, Vol.79, p.66-73

2016

Volltextzugriff (PDF)

Cervical Dorsal Rhizotomy Increases Brain-Derived Neurotrophic Factor and Neurotrophin-3 Expression in the Ventral Spinal Cord

The Journal of neuroscience, 2000-05, Vol.20 (10), p.77-RC77

2000

Volltextzugriff (PDF)

Tumor-derived death receptor 6 modulates dendritic cell development

Cancer Immunology, Immunotherapy, 2008-06, Vol.57 (6), p.777-787

2008

Volltextzugriff (PDF)

Lebrikizumab Decreases Inflammatory Biomarkers in Patients with Asthma: Data from Randomized Phase 3 Trials (LAVOLTA I and II)

Journal of allergy and clinical immunology, 2023-02, Vol.151 (2), p.AB195-AB195

2023

Volltextzugriff (PDF)

628 - Clinical measures of improvement in atopic dermatitis are correlated with reductions in relevant biomarkers in patients treated with lebrikizumab

British journal of dermatology (1951), 2024-08, Vol.191 (Supplement_2)

2024

Volltextzugriff (PDF)

495 - Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis

British journal of dermatology (1951), 2024-02, Vol.190 (Supplement_2), p.ii4-ii5

2024

Volltextzugriff (PDF)

42186 Prurigo nodularis blood signature is characterized by increases in IL-13 and caspase 8

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB78-AB78

2023

Volltextzugriff (PDF)

ELEVATED TRYPTASE, NERVE GROWTH FACTOR, NEUROTROPHIN-3 AND GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR LEVELS IN THE URINE OF INTERSTITIAL CYSTITIS AND BLADDER CANCER PATIENTS

The Journal of urology, 1999-02, Vol.161 (2), p.438-442

1999

Volltextzugriff (PDF)

732 - EASI 90 response sustained up to 38 weeks after lebrikizumab withdrawal despite negligible serum concentrations

British journal of dermatology (1951), 2024-08, Vol.191 (Supplement_2)

2024

Volltextzugriff (PDF)

LIGHT‐deficiency impairs CD8+ T cell expansion, but not effector function

International immunology, 2003-07, Vol.15 (7), p.861-870

2003

Volltextzugriff (PDF)

IL-33 drives alum-induced cytokine production and provides a robust secondary antibody response independently of alum (CCR4P.211)

The Journal of immunology (1950), 2015-05, Vol.194 (1_Supplement), p.118-118.11

2015

Volltextzugriff (PDF)

IL-33 antibody failed to demonstrate benefit in a phase 2 double-blind, randomised placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis

British journal of dermatology (1951), 2022-04

2022

Volltextzugriff (PDF)

Generation and Characterization of Torudokimab

Journal of inflammation research, 2021-08, Vol.14, p.3823

2021

Volltextzugriff (PDF)

A p74 common gamma receptor chain isoform facilitates IL-2 and IL-15 responses by the myelomonocytic cell line Tf-1β2

Journal of leukocyte biology, 2001-03, Vol.69 (3), p.419-425

2001

Volltextzugriff (PDF)

An Acid-Treatment Method for the Enhanced Detection of GDNF in Biological Samples

Experimental neurology, 1997-06, Vol.145 (2), p.592-596

1997

Volltextzugriff (PDF)

Facile generation and use of immunogenic polypeptide fusions to a sparingly soluble non-antigenic protein carrier

Journal of immunological methods, 2000-03, Vol.236 (1), p.53-69

2000

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(16)
Animals
(9)
Humans
(8)
Mice
(7)
Immunology
(6)
Biological And Medical Sciences
(4)
Cytokines
(4)
Dermatology
(4)
Female
(4)
Glial Cell Line-Derived Neurotrophic Factor
(4)
Male
(4)
Mice, Knockout
(4)
Neurosciences
(4)
Neurosciences & Neurology
(4)
Allergy
(3)
Health Aspects
(3)
Il-33
(3)
Itch
(3)
Medicine
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: A cluster analysis

Serum Interleukin-13 and Caspase 8 are Elevated in Prurigo Nodularis

Interleukin‐33 antibody failed to demonstrate benefit in a phase II, double‐blind, randomized, placebo‐controlled study in adult patients with moderate‐to‐severe atopic dermatitis

Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: A cluster analysis

IL-33 released by alum is responsible for early cytokine production and has adjuvant properties

Human mast cells release the migraine-inducing factor pituitary adenylate cyclase-activating polypeptide (PACAP)

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab

Interleukin-33 Contributes Toward Loss of Tolerance by Promoting B-Cell-Activating Factor of the Tumor-Necrosis-Factor Family (BAFF)-Dependent Autoantibody Production

Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33

Elevated levels of Interleukin (IL)-33 induce bone pathology but absence of IL-33 does not negatively impact normal bone homeostasis

Cervical Dorsal Rhizotomy Increases Brain-Derived Neurotrophic Factor and Neurotrophin-3 Expression in the Ventral Spinal Cord

Tumor-derived death receptor 6 modulates dendritic cell development

Lebrikizumab Decreases Inflammatory Biomarkers in Patients with Asthma: Data from Randomized Phase 3 Trials (LAVOLTA I and II)

628 - Clinical measures of improvement in atopic dermatitis are correlated with reductions in relevant biomarkers in patients treated with lebrikizumab

495 - Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis

42186 Prurigo nodularis blood signature is characterized by increases in IL-13 and caspase 8

ELEVATED TRYPTASE, NERVE GROWTH FACTOR, NEUROTROPHIN-3 AND GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR LEVELS IN THE URINE OF INTERSTITIAL CYSTITIS AND BLADDER CANCER PATIENTS

732 - EASI 90 response sustained up to 38 weeks after lebrikizumab withdrawal despite negligible serum concentrations

LIGHT‐deficiency impairs CD8+ T cell expansion, but not effector function

IL-33 drives alum-induced cytokine production and provides a robust secondary antibody response independently of alum (CCR4P.211)

IL-33 antibody failed to demonstrate benefit in a phase 2 double-blind, randomised placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis

Generation and Characterization of Torudokimab

A p74 common gamma receptor chain isoform facilitates IL-2 and IL-15 responses by the myelomonocytic cell line Tf-1β2

An Acid-Treatment Method for the Enhanced Detection of GDNF in Biological Samples

Facile generation and use of immunogenic polypeptide fusions to a sparingly soluble non-antigenic protein carrier

Suchergebnisse filtern